首页> Clinical genitourinary cancer> Docetaxel Versus Androgen-Receptor Signaling Inhibitors (ARSI) as Second-Line Therapy After Failure of First-Line Alternative ARSI for the Elderly ≥ 75 Years Old With Metastatic Castration-Resistant Prostate Cancer (mCRPC): A SPARTACUSS-Meet-URO 26 Real-World Study.

Docetaxel Versus Androgen-Receptor Signaling Inhibitors (ARSI) as Second-Line Therapy After Failure of First-Line Alternative ARSI for the Elderly ≥ 75 Years Old With Metastatic Castration-Resistant Prostate Cancer (mCRPC): A SPARTACUSS-Meet-URO 26 Real-World Study.

导出 LinkOut

翻译打印收藏纠错

第一作者： Anna,Patrikidou

第一单位： Department of Medical Oncology and Early Drug Development Department, Gustave Roussy Institute, Villejuif, France.

作者： Anna,Patrikidou ^[1] ; Calogero,Saieva ^[2] ; Richard,Lee-Ying ^[3] ; Pier Vitale,Nuzzo ^[4] ; Talal El,Zarif ^[5] ; Heather,McClure ^[5] ; Matthew,Davidsohn ^[5] ; Marc,Eid ^[5] ; Gian Paolo,Spinelli ^[6] ; Fabio,Catalano ^[7] ; Malvina,Cremante ^[7] ; Giuseppe,Fotia ^[8] ; Sabrina,Rossetti ^[9] ; Loana,Valenca ^[10] ; Charles,Vauchier ^[11] ; Carlotta,Ottanelli ^[12] ; Livia,Andrade ^[10] ; Vincenzo,Gennusa ^[13] ; Ricardo Pereira,Mestre ^[14] ; Giuseppe,Fornarini ^[7] ; Sandro,Pignata ^[9] ; Giuseppe,Procopio ^[8] ; Daniele,Santini ^[15] ; Praful,Ravi ^[5] ; Christopher,Sweeney ^[16] ; Daniel,Heng ^[3] ; Ugo,De Giorgi ^[17] ; Karim,Fizazi ^[11] ; Antonio,Russo ^[13] ; Edoardo,Francini ^[18] ; SPARTACUSS Group

作者单位： Department of Medical Oncology and Early Drug Development Department, Gustave Roussy Institute, Villejuif, France. ^[1] Cancer Risk Factors and Lifestyle Epidemiology Unit-ISPRO, Florence, Italy. ^[2] Tom Baker Cancer Centre, Calgary, Alberta, Canada. ^[3] Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY. ^[4] Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA. ^[5] Division of Medical Oncology, Casa della Salute di Aprilia, Latina, Sapienza University of Rome, Italy. ^[6] Medical Oncology Unit 1, IRCCS Ospedale Policlinico San Martino, Genova, Italy. ^[7] Medical Oncology Department, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy. ^[8] Instituto Nazionale Tumori IRCCS Fondazione G. Pascale, Naples, Italy. ^[9] Instituto D'Or de Pesquisa e Ensino, Salvador, Brazil. ^[10] Department of Medical Oncology, Gustave Roussy Institute, Villejuif, France. ^[11] University of Florence, Florence, Italy. ^[12] Department of Surgical, Oncological and Oral Sciences, Section of Medical Oncology, University of Palermo, Palermo, Italy. ^[13] Oncology Institute of Southern Switzerland, Bellinzona, Switzerland. ^[14] Oncology Unit, Umberto I hospital, Rome, Italy. ^[15] South Australian Immunogenomics Cancer Institute, University of Adelaide, Adelaide, Australia. ^[16] IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST), Meldola, Italy. ^[17] Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy. Electronic address: edoardo.francini@unifi.it. ^[18]

关键词 Abiraterone Enzalutamide Geriatric oncology Older men Taxane